Jim Chanos was recently on CNBC talking about the new opportunities he sees in the market for meaningful downside. He thinks serial acquirers who aren't growing organically are a good target for shorting. He wouldn't name names bud alluded that the biotech industry was particularly rife with this problem - makes me wonder if he is short Endo Health Solutions (ENDP) or Valeant Pharmaceuticals (VRX) which would be bold since that is a favorite among many hedge fund managers. Enjoy:
No comments:
Post a Comment